徐坤，教授，博士，博士生导师

科研方向：

疫苗学

抗原免疫表位及中和抗体

联系方式

通讯：江苏省南京市江宁区龙眠大道101号基础医学病原生物学系，邮编211166

电邮：xukun2011@163.com

简介

徐坤，2018年中国科学院大学遗传学博士毕业，现为南京医科大学基础医学院病原生物学系教授，博士生导师。研究方向主要为重要传染性病原的疫苗研究，结合免疫表位和抗体分析，利用结构生物学等方法，设计和开发安全高效的新型疫苗。主持国家自然科学基金青年基金和国家重点研发计划项目课题。近年来以第一作者和通讯作者（含共同）在Cell, N Engl J Med, PLoS Pathog, Med, Emerg Microbes Infect等学术期刊发表多篇论文。

学术兼职

中国生物工程学会疫苗工程专业委员会副秘书长

承担科研课题

1. 国家自然科学基金青年基金“预防新冠病毒变异株的蛋白疫苗激活抗体反应广谱性的机制研究”，2023-01至2025-12，主持

2. 国家重点研发计划“重要预防性疫苗免疫应答的精准医学研究”项目“疫苗应答机制的动物模型研究”课题负责人，2023-11至2026-11，主持

代表性论文

1. Xu, K.^#, Song, Y.^#, Dai, L., Zhang, Y., Lu, X., Xie, Y., Zhang, H., Cheng, T., Wang, Q., Huang, Q., Bi, Y., Liu, W. J., Liu, W., Li, X., Qin, C., Shi, Y., Yan, J., Zhou, D.*, and Gao, G. F.* Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage. J Virol. 2018, 92(6):e01722-17.

2. Dai, L.^#*, Zheng, T.^#, Xu, K.^#, Han, Y.^#, Xu, L.^#, Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., Yang, M., Li, Y., Cheng, H., Yuan, Y., Zhang, W., Ke, C., Wong, G., Qi, J., Qin, C.*, Yan, J.*, and Gao, G. F.* A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020, 182(3):722-733.e11.

3. Xu, K.^#, An, Y.^#, Li, Q.^#, Huang, W.^#, Han, Y., Zheng, T., Fang, F., Liu, H., Liu, C., Gao, P., Xu, S., Liu, X., Zhang, R., Zhao, X., Liu, W. J., Bi, Y., Wang, Y., Zhou, D., Wang, Q.*, Hou, W.*, Xia, Q.*, Gao, G. F.*, and Dai, L.* Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Emerg Microbes Infect. 2021, 10(1):1574-1588.

4. Xu, K.^#, Dai, L., and Gao, G. F.* Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. Int Immunol. 2021, 33(10):529-540.

5. Dai, L.^#*, Xu, K.^#, Li, J.^#, Huang, Q., Song, J., Han, Y., Zheng, T., Gao, P., Lu, X., Yang, H., Liu, K., Xia, Q., Wang, Q., Chai, Y., Qi, J., Yan, J.*, and Gao, G. F.* Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch. Nat Immunol. 2021, 22(8):958-968.

6. Liu, J.^#, Xu, K.^#, Xing, M.^#, Zhuo, Y.^#, Guo, J.^#, Du, M., Wang, Q., An, Y., Li, J., Gao, P., Wang, Y., He, F., Guo, Y., Li, M., Zhang, Y., Zhang, L., Gao, G. F.*, Dai, L.*, and Zhou, D.* Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. Cell Discov. 2021, 7(1):123.

7. Xu, K.^#, Gao, P.^#, Liu, S.^#, Lu, S.^#, Lei, W.^#, Zheng, T.^#, Liu, X., Xie, Y., Zhao, Z., Guo, S., Tang, C., Yang, Y., Yu, W., Wang, J., Zhou, Y., Huang, Q., Liu, C., An, Y., Zhang, R., Han, Y., Duan, M., Wang, S., Yang, C., Wu, C., Liu, X., She, G., Liu, Y., Zhao, X., Xu, K., Qi, J., Wu, G.*, Peng, X.*, Dai, L.*, Wang, P.*, and Gao, G. F.* Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell. 2022, 185(13):2265-2278.e14.

8. Han, Y.^#, An, Y.^#, Chen, Q.^#, Xu, K.^#, Liu, X.^#, Xu, S., Duan, H., Vogel, A. B., Sahin, U., Wang, Q.*, Dai, L.*, and Gao, G. F.* mRNA vaccines expressing homo-prototype/Omicron and hetero-chimeric RBD-dimers against SARS-CoV-2. Cell Res. 2022, 32(11):1022-1025.

9. Xu, K.^#, Fan, C., Han, Y., Dai, L., and Gao, G. F.* Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. Int Immunol. 2022, 34(12):595-607.

10. An, Y.^#, Li, S.^#, Jin, X.^#, Han, J. B.^#, Xu, K.^#, Xu, S.^#, Han, Y., Liu, C., Zheng, T., Liu, M., Yang, M., Song, T. Z., Huang, B., Zhao, L., Wang, W., A, R., Cheng, Y., Wu, C., Huang, E., Yang, S., Wong, G., Bi, Y., Ke, C., Tan, W.*, Yan, J.*, Zheng, Y. T.*, Dai, L.*, and Gao, G. F.* A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerg Microbes Infect. 2022, 11(1):1058-1071.

11. Li, D.^#, Duan, M., Wang, X., Gao, P., Zhao, X., Xu, K.*, and Gao, G. F. Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines. N Engl J Med. 2023, 388(12):1142-1145.

12. Zhang, Y.^#, Kang, X.^#, Liu, S.^#, Han, P.^#, Lei, W.^#, Xu, Ke^#, Xu, Z., Gao, Z., Zhou, X., An, Y., Han, Y., Liu, K., Zhao, X., Dai, L., Wang, P.*, Wu, G.*, Qi, J.*, Xu, K*, and Gao, G. F.* Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7. PLoS Pathog. 2023, 19(9):e1011659.

13. Duan, M.^#, Duan, H., An, Y., Zheng, T., Wan, S., Wang, H., Zhao, X., Dai, L.*, Xu, K.*, and Gao, G. F. A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5. Emerg Microbes Infect. 2023, 12(1):e2179357.

14. He, Q.^#, An, Y.^#, Zhou, X.^#, Xie, H.^#, Tao, L.^#, Li, D., Zheng, A., Li, L., Xu, Z., Yu, S., Wang, R., Hu, H., Liu, K., Wang, Q., Dai, L., Xu, K.*, and Gao, G. F.* Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies. Med. 2024, 5(5):401-413.e4.

15. Zhao, T.^#, Liu, S., Wang, P., Zhang, Y., Kang, X., Pan, X., Li, L., Li, D., Gao, P., An, Y., Song, H., Liu, K., Qi, J., Zhao, X., Dai, L., Liu, P.*, Wang, P., Wu, G., Zhu, T.*, Xu, K.*, Li, Y., and Gao, G. F. Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris. PLoS Pathog. 2024. 20(8):e1012487.

16. Xu, K.^#, An, Y.^#, Liu, X.^#, Xie, H.^#, Li, D., Yang, T., Duan, M., Wang, Y., Zhao, X., Dai, L., and Gao, G. F.* Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera. NPJ Vaccines. 2024. 9(1): 215.

授权专利

1. 高福，戴连攀，徐坤，郑天依；一种新冠病毒Delta和Omicron变异株嵌合抗原、其制备方法和应用，ZL202210340144.6

2. 高福，严景华，徐坤，戴连攀，周东明；一种基于黑猩猩腺病毒载体的寨卡病毒疫苗及其制备方法，ZL201711320081.3